Actym Therapeutics (Series A)

Funding Details
Date Award
May 20, 2025
Vertical
Biotechnology
Funding URL
View Funding Page
Funding Amount:
$34,000,000

Company Info
Founding Year
2017
Founders
Christopher Thanos Ph.D., Laura Hix Glickman Ph.D., Amit Kumar Ph.D.
Company Description
Actym Therapeutics has developed a microbial-based immunotherapy platform called STACT (S. Typhimurium Attenuated Cancer Therapy) that specifically enriches in many types of solid tumors and not in healthy tissue, delivering multiplexed immuno-modulatory payloads directly to tumor-resident immune cells.
Market
Immunotherapy
Location
Berkeley, California, USA
Coinvestors
Boehringer Ingelheim Venture Fund, Illumina Ventures, JLo Ventures, Korea Investment Partners, Panacea Ventures

Links